Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Exact Sciences Corp (EXAS)  
$58.79 4.45 (7.04%) as of 4:30 Thu 4/25


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 177,680,000
Market Cap: 10.45(B)
Last Volume: 2,648,495 Avg Vol: 1,912,015
52 Week Range: $56.27 - $99.04
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Biotechnology

Member Indexes:
    NASDAQ COMPOSITE     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  568
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 101,681 106,560 180,043 288,496
Total Sell Value $6,108,748 $6,460,355 $12,383,121 $18,565,448
Total People Sold 10 10 11 11
Total Sell Transactions 41 44 58 92
End Date 2024-01-25 2023-10-24 2023-04-25 2022-04-25

   
Records found: 777
  Page 1 of 32  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Baranick Brian EVP, GM., Precision Oncology   •       –      –    2024-04-02 4 AS $79.43 $73,393 D/D (924) 13,171 -17%     
   Condella Sarah EVP, Human Resources   •       –      –    2024-04-01 4 AS $70.00 $140,000 D/D (2,000) 71,787 -13%     
   Condella Sarah EVP, Human Resources   •       –      –    2024-03-28 4 AS $70.00 $140,000 D/D (2,000) 73,787 -12%     
   Levangie Daniel J Director   –       •      –    2024-03-01 4 AS $57.50 $287,500 D/D (5,000) 22,975 3%     
   Conroy Kevin T President and CEO   •       •      –    2024-03-01 4 AS $59.32 $490,636 D/D (8,271) 1,299,496 3%     
   Condella Sarah EVP, Human Resources   •       –      –    2024-03-01 4 AS $59.32 $102,268 D/D (1,724) 75,787 3%     
   Elliott Jeffrey Thomas Chief Financial Officer   •       –      –    2024-03-01 4 AS $59.32 $143,080 D/D (2,412) 10,933 3%     
   Cunningham Everett Chief Commercial Officer   •       –      –    2024-03-01 4 AS $59.32 $143,080 D/D (2,412) 46,179 3%     
   Doyle James Edward Director   –       •      –    2024-03-01 4 AS $57.50 $115,000 D/D (2,000) 50,110 3%     
   Herriott James General Counsel   •       –      –    2024-03-01 4 AS $59.32 $51,134 D/D (862) 9,125 3%     
   Baranick Brian Gen. Mgr., Precision Oncology   •       –      –    2024-03-01 4 AS $59.32 $137,800 D/D (2,323) 14,095 3%     
   Orville Jacob A General Manager, Screening   •       –      –    2024-03-01 4 AS $59.32 $127,775 D/D (2,154) 14,324 3%     
   Conroy Kevin T President and CEO   •       •      –    2024-02-29 4 OE $0.00 $0 D/D 18,143 1,307,767     -
   Condella Sarah EVP, Human Resources   •       –      –    2024-02-29 4 OE $0.00 $0 D/D 3,779 77,511     -
   Elliott Jeffrey Thomas Chief Financial Officer   •       –      –    2024-02-29 4 OE $0.00 $0 D/D 5,291 13,345     -
   Cunningham Everett Chief Commercial Officer   •       –      –    2024-02-29 4 OE $0.00 $0 D/D 5,291 48,591     -
   Herriott James General Counsel   •       –      –    2024-02-29 4 OE $0.00 $0 D/D 1,890 9,987     -
   Baranick Brian Gen. Mgr., Precision Oncology   •       –      –    2024-02-29 4 OE $0.00 $0 D/D 4,724 16,418     -
   Orville Jacob A General Manager, Screening   •       –      –    2024-02-29 4 OE $0.00 $0 D/D 4,724 16,478     -
   Condella Sarah EVP, Human Resources   •       –      –    2024-02-27 4 AS $56.89 $106,953 D/D (1,880) 73,732 7%     
   Herriott James General Counsel   •       –      –    2024-02-27 4 AS $56.89 $44,602 D/D (784) 8,097 7%     
   Conroy Kevin T President and CEO   •       •      –    2024-02-27 4 AS $56.89 $356,302 D/D (6,263) 1,289,624 7%     
   Elliott Jeffrey Thomas Chief Financial Officer   •       –      –    2024-02-27 4 AS $56.89 $154,172 D/D (2,710) 8,054 7%     
   Orville Jacob A General Manager, Screening   •       –      –    2024-02-27 4 AS $56.89 $106,896 D/D (1,879) 11,754 7%     
   Cunningham Everett Chief Commercial Officer   •       –      –    2024-02-27 4 AS $56.89 $207,535 D/D (3,648) 43,300 7%     
  777 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 32
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us